Pancreas · 2026
Outcomes of Post-Endoscopic Ultrasound Pancreatic Cancer Compared to Detected Pancreatic Cancer: A Multicenter Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Karna Rahul, Khataniar Himsikhar, Ta'ani Omar Al, Arayakarnkul Suchapa, Bilal Mohammad, Umar Shifa
Аннотация
BACKGROUND AND AIMS: Endoscopic ultrasound (EUS) can detect pre-malignant lesions in pancreas. Despite advances in training, EUS remains an operator dependent procedure and interval pancreatic cancer (PC) can be diagnosed after a preceding cancer-negative EUS. We aim to study outcomes of PC occurring after a EUS negative for cancer.
METHODS: We utilized the TriNetX multi-institutional database to assess patients with PC and a preceding EUS. Patients whose EUS occurred less than 6 months before PC diagnosis were categorized as detected pancreatic cancer (D-PC), while those with EUS that did not detect PC between 6 and 18 months before PC diagnosis were categorized as post EUS-pancreatic cancer (PEPC). Propensity matched cohort analysis was performed after controlling for covariates to assess surgery, chemotherapy, hospitalization and all-cause mortality.
RESULTS: Out of 20,828 included PC patients, 5.4% (n=1,127 ) were PEPC and 94.6% (n=19,701) were D-PC. At three years, PEPC cohort had significantly lower chemotherapy utilization (33.07% vs. 45.46%), surgery (9.53% vs 22.37%), all cause hospitalization (53.57% vs 69.70%) and all-cause mortality (27.90% vs. 33.42%) compared to D-PC. Predictors of mortality in PEPC cohort include White race (aHR 1.191), type 2 diabetes mellitus (aHR 1.144), nicotine use (aHR 1.233), location in head (aHR 1.319) and body (aHR 1.225) of pancreas.
CONCLUSIONS: Nearly 5.4% pancreatic cancer occur after negative EUS in the previous 6-18 months. D-PC had higher chance of surgical resection and chemotherapy but also higher rates of mortality at 3-years. Further large scale studies with patient and procedure level data assessment to allow root-cause analysis is needed to determine its etiology and associated factors to limit its incidence.
METHODS: We utilized the TriNetX multi-institutional database to assess patients with PC and a preceding EUS. Patients whose EUS occurred less than 6 months before PC diagnosis were categorized as detected pancreatic cancer (D-PC), while those with EUS that did not detect PC between 6 and 18 months before PC diagnosis were categorized as post EUS-pancreatic cancer (PEPC). Propensity matched cohort analysis was performed after controlling for covariates to assess surgery, chemotherapy, hospitalization and all-cause mortality.
RESULTS: Out of 20,828 included PC patients, 5.4% (n=1,127 ) were PEPC and 94.6% (n=19,701) were D-PC. At three years, PEPC cohort had significantly lower chemotherapy utilization (33.07% vs. 45.46%), surgery (9.53% vs 22.37%), all cause hospitalization (53.57% vs 69.70%) and all-cause mortality (27.90% vs. 33.42%) compared to D-PC. Predictors of mortality in PEPC cohort include White race (aHR 1.191), type 2 diabetes mellitus (aHR 1.144), nicotine use (aHR 1.233), location in head (aHR 1.319) and body (aHR 1.225) of pancreas.
CONCLUSIONS: Nearly 5.4% pancreatic cancer occur after negative EUS in the previous 6-18 months. D-PC had higher chance of surgical resection and chemotherapy but also higher rates of mortality at 3-years. Further large scale studies with patient and procedure level data assessment to allow root-cause analysis is needed to determine its etiology and associated factors to limit its incidence.